.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
Express Scripts
Farmers Insurance
Boehringer Ingelheim
Johnson and Johnson
Cerilliant
Cipla
Moodys
QuintilesIMS
Merck

Generated: July 22, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 065055

« Back to Dashboard
NDA 065055 describes DOXYCYCLINE, which is a drug marketed by Heritage Pharms Inc, Mylan Labs Ltd, Zydus Pharms Usa Inc, Mylan, Sandoz Inc, Lupin Ltd, Watson Labs, G And W Labs Inc, West-ward Pharms Int, Sun Pharm Inds Ltd, Chartwell Life Sci, Par Pharm, Impax Labs Inc, Sun Pharm Inds, Mylan Pharms Inc, Lannett, Hikma Intl Pharms, Mutual Pharm, Halsey, Actavis Labs Fl Inc, Pvt Form, Actavis Elizabeth, Vintage Pharms, Heather, Interpharm, Ivax Sub Teva Pharms, Mayne Pharma Inc, Superpharm, Caribe Holdings, Ranbaxy, Medicis, Epic Pharma Llc, Pliva, Larken Labs, Amneal Pharms, Warner Chilcott, and Prinston Inc, and is included in seventy NDAs. It is available from thirty-four suppliers. Additional details are available on the DOXYCYCLINE profile page.

The generic ingredient in DOXYCYCLINE is doxycycline hyclate. There are twenty-seven drug master file entries for this compound. Eighty-nine suppliers are listed for this compound. Additional details are available on the doxycycline hyclate profile page.

Summary for NDA: 065055

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Therapeutic Class:Antibacterials
Dermatological Agents
Formulation / Manufacturing:see details

Suppliers and Packaging for NDA: 065055

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
DOXYCYCLINE
doxycycline
CAPSULE;ORAL 065055 ANDA PharmaDerm a division of Fougera Pharmaceuticals Inc. 10337-815 10337-815-06 60 CAPSULE in 1 BOTTLE (10337-815-06)
DOXYCYCLINE
doxycycline
CAPSULE;ORAL 065055 ANDA Par Pharmaceutical, Inc. 49884-305 49884-305-02 60 CAPSULE in 1 BOTTLE (49884-305-02)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 50MG BASE
Approval Date:Dec 1, 2000TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 100MG BASE
Approval Date:Dec 1, 2000TE:ABRLD:No

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 150MG BASE
Approval Date:Jul 15, 2005TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Cipla
Federal Trade Commission
Argus Health
Farmers Insurance
Cantor Fitzgerald
Deloitte
Novartis
Citi
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot